EFPIA welcomes IMI2 to boost industry investment in Europe

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has welcomed the adoption of the second Innovate Medicines Initiative (IMI2) regulation by the European Council.

It is hoped that it will continue the success of the first IMI, a public-private partnership between the European Union and the EFPIA that aims to advance research and development, particularly in areas of unmet medical need. IMI2 will develop IMI’s vision of service to public health needs, having looked to the World Health Organization’s Report on Priority Medicines for Europe and the World in determining its Strategic Research Agenda (SRA). The SRA, an essential element of the evolution from IMI to IMI2, was determined with input from more than 80 organisations, including regulators, patients, academia and learned societies. The initial focus of IMI2 will be on fields such as neuro-degeneration, metabolic disorders, immune-mediated diseases, infections and translational safety.

Tangible outcomes for patients